---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-027180"
form_type: "8-K"
ticker: "VTGN"
cik: "0001411685"
company_name: "Vistagen Therapeutics, Inc."
filed_at: "2023-09-29T23:59:59+00:00"
generated_at: "2026-06-10T06:50:51.374994+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Vistagen stockholders re-elect directors, approve equity plan increase to 1M shares

## Summary
- Seven director nominees re-elected; votes for ranged from 1.44M to 1.67M, withholds 416k to 642k.
- Advisory say-on-pay approved with 1.38M for, 607k against, 96k abstain.
- Amendment to 2019 Omnibus Equity Incentive Plan approved: authorized shares increased from 600k to 1M.
- Ratification of WithumSmith+Brown as auditors for FY ending March 31, 2024 approved (3.93M for).

## SEC filing metadata
- accession: 0001437749-23-027180
- form_type: 8-K
- ticker: VTGN
- cik: 0001411685
- company_name: Vistagen Therapeutics, Inc.
- filed_at: 2023-09-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411685/000143774923027180/0001437749-23-027180-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411685/000143774923027180/vtgn20230921_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-027180
- JSON: https://secwatch.observer/filing/0001437749-23-027180.json
- Plain text: https://secwatch.observer/filing/0001437749-23-027180.txt

## Key facts
- Shareholder Votes
  Vistagen Therapeutics, Inc. shareholders approved Election of Directors at the 2023-09-25 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-09-25
  source text: Proposal No. 1 – Election of Directors For Withheld Ann M. Cunningham, MBA 1,443,789 641,810
  evidence_url: https://www.sec.gov/Archives/edgar/data/1411685/000143774923027180/0001437749-23-027180-index.htm
- Shareholder Votes
  Vistagen Therapeutics, Inc. shareholders approved Advisory Vote to Approve Executive Compensation (Say-on-Pay Proposal) at the 2023-09-25 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-09-25
  source text: Proposal No. 2 – Advisory Vote to Approve Executive Compensation (Say-on-Pay Proposal) For Against Abstain Votes 1,382,535 607,263 95,801
  evidence_url: https://www.sec.gov/Archives/edgar/data/1411685/000143774923027180/0001437749-23-027180-index.htm
- Shareholder Votes
  Vistagen Therapeutics, Inc. shareholders approved Ratification of Appointment of Auditors at the 2023-09-25 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-09-25
  source text: Proposal No. 4 – Ratification of Appointment of Auditors For Against Abstain Votes 3,933,402 334,951 42,733
  evidence_url: https://www.sec.gov/Archives/edgar/data/1411685/000143774923027180/0001437749-23-027180-index.htm
- Shareholder Votes
  Vistagen Therapeutics, Inc. shareholders approved Amendment to the Vistagen Therapeutics, Inc. Amended and Restated 2019 Omnibus Equity Incentive Plan at the 2023-09-25 meeting.
  - Proposal: equity plan
  - Outcome: passed
  - Meeting: 2023-09-25
  source text: Proposal No. 3 – Amendment to the Vistagen Therapeutics, Inc. Amended and Restated 2019 Omnibus Equity Incentive Plan For Against Abstain Votes 1,389,517 667,326 28,756
  evidence_url: https://www.sec.gov/Archives/edgar/data/1411685/000143774923027180/0001437749-23-027180-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.